March 28, 2019 09:39 AM EDTUpdated 02:02 PM

Sure Hervé Hoppenot took a big cut in compensation after a pipeline disaster. But he still outscored the only woman on the list

John Carroll

Editor & Founder

After a brutal year at the helm, Incyte CEO Hervé Hoppenot took a big cut in annual compensation for 2018 — but he still made more than GSK CEO Emma Walmsley.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Sure Hervé Hoppenot took a big cut in compensation after a pipeline disaster. But he still outscored the only woman on the list

John Carroll

Editor & Founder

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Large pharma companies spell out reasons why tariffs will harm US investments

Merck, Daiichi Sankyo scrap FDA application for HER3 ADC after survival miss

Supreme Court to keep mulling state PBM dispute as US urges justices to decline case

DNA giant Illumina spawned an ecosystem of competitors and customers

Intellia reports case of liver toxicity in ATTR gene editing study

From weeks to days: how Aizon Intelligent Agents transform pharma validation

Sure Hervé Hop­penot took a big cut in com­pen­sa­tion af­ter a pipeline dis­as­ter. But he still outscored the on­ly woman on the list

Editor & Founder

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Sure Hervé Hoppenot took a big cut in compensation after a pipeline disaster. But he still outscored the only woman on the list